AngioDynamics gains expanded coverage for VenaCure:
This article was originally published in Clinica
AngioDynamics is to see its VenaCure endovenous laser ablation system - formerly known as ELVS - added to US healthcare insurance company Anthem's list of Medicare-covered treatments for varicose veins. With this expanded coverage, "the total number of eligible covered lives for the VenaCure procedure now exceeds 150 million [patients] in the US", says Queensbury, New York-based AngioDynamics. The VenaCure system, cleared by the FDA in 2002, is marketed as a quick, no-fuss, minimally invasive alternative to the traditional ligation and stripping method of treating varicose veins. It is performed on an outpatient basis and under local anaesthetic.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.